Acurx Pharmaceuticals LLC
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potenti… Read more
Acurx Pharmaceuticals LLC (ACXP) - Total Assets
Latest total assets as of September 2025: $6.11 Billion USD
Based on the latest financial reports, Acurx Pharmaceuticals LLC (ACXP) holds total assets worth $6.11 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Acurx Pharmaceuticals LLC - Total Assets Trend (2019–2024)
This chart illustrates how Acurx Pharmaceuticals LLC’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Acurx Pharmaceuticals LLC - Asset Composition Analysis
Current Asset Composition (December 2024)
Acurx Pharmaceuticals LLC's total assets of $6.11 Billion consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 96.1% |
| Accounts Receivable | $51.13K | 1.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Acurx Pharmaceuticals LLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Acurx Pharmaceuticals LLC's current assets represent 100.0% of total assets in 2024, unchanged from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 96.1% of total assets in 2024, down from 98.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 1.3% of total assets.
Acurx Pharmaceuticals LLC Competitors by Total Assets
Key competitors of Acurx Pharmaceuticals LLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Acurx Pharmaceuticals LLC - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Acurx Pharmaceuticals LLC generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Acurx Pharmaceuticals LLC is currently not profitable relative to its asset base.
Acurx Pharmaceuticals LLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.39 | 1.80 | 6.82 |
| Quick Ratio | 2.39 | 1.80 | 6.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.44 Billion | $ 2.66 Million | $ 2.75 Million |
Acurx Pharmaceuticals LLC - Advanced Valuation Insights
This section examines the relationship between Acurx Pharmaceuticals LLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.50 |
| Latest Market Cap to Assets Ratio | 1.41 |
| Asset Growth Rate (YoY) | -50.0% |
| Total Assets | $3.86 Million |
| Market Capitalization | $5.45 Million USD |
Valuation Analysis
Above Book Valuation: The market values Acurx Pharmaceuticals LLC's assets above their book value (1.41 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Acurx Pharmaceuticals LLC's assets decreased by 50.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Acurx Pharmaceuticals LLC (2019–2024)
The table below shows the annual total assets of Acurx Pharmaceuticals LLC from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.86 Million | -49.96% |
| 2023-12-31 | $7.71 Million | -17.78% |
| 2022-12-31 | $9.38 Million | -29.25% |
| 2021-12-31 | $13.25 Million | +311.11% |
| 2020-12-31 | $3.22 Million | +27.36% |
| 2019-12-31 | $2.53 Million | -- |